Study highlights VE303’s potential in reducing recurrent CDI
Category: News
Orphan drug designation offers development incentives and potential market exclusivity
Phase 3 trial shows promising pain relief for acute pain patients
Europe’s first biomarker trial seeks to prevent Crohn’s Disease onset
NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care
Preclinical data highlights potential in treating Alzheimer’s disease
Combination therapy shows superior survival benefit over standard treatment
Cell and Gene Therapy Catapult reveals significant growth in UK trials
Collaboration aims to enhance accessibility of medicines information